UK policy statements on testosterone deficiency.
To address widespread media and scientific concerns over the appropriate treatment of TDS with Testosterone Therapy (T Therapy), the Executive Committee of the British Society for Sexual Medicine developed eight consensus statements, based on current scientific evidence to address these controversial issues. These statements were in no-way designed to replace the published evidence-based guidelines on the subject developed by various professional organisations, but to provide specific answers to several current controversial issues. This review examined evidence from Medline, EMBASE and Cochrane searches on HG, T Therapy and cardiovascular safety from May 2005 to May 2015, which revealed 1714 articles, with 52 clinical trials and 32 placebo-controlled randomised controlled trials. The task force developed the following eight key statements.
Good Hope Hospital, Birmingham, UK.|University of Bedfordshire, Luton, UK.
Geoffrey
G
Hackett
Faculty of Health & Human Sciences, University of Hertfordshire, Hatfield, UK.|The Prostate Centre, London, UK.
Michael
http://orcid.org/0000-0002-5429-7714
M
Kirby
White House Surgery, Chipping Norton, UK.|British Society for Sexual Medicine (BSSM), Staffordshire, UK.
David
D
Edwards
Barnsley Hospital, Barnsley, UK.|University of Sheffield Medical School, Sheffield, UK.|Royal Hallamshire Hospital, Sheffield, UK.
T Hugh
TH
Jones
Backwell & Nailsea Medical Group, Bristol, UK.|Primary Care Urology Society, London, UK.
Jonathan
J
Rees
British Society for Sexual Medicine (BSSM), Staffordshire, UK.|Department of Urology and NIHR Biomedical Research Centre University College London Hospitals, London, UK.
Asif
A
Muneer
D032921:Consensus; D019317:Evidence-Based Medicine; D006801:Humans; D017410:Practice Guidelines as Topic / Q000592:standards*; D011785:Quality Assurance, Health Care; D016032:Randomized Controlled Trials as Topic; D012955:Societies, Medical; D013739:Testosterone / Q000172:deficiency*; D006113:United Kingdom
D013739:Testosterone